Skip to content

Evaluation of the clinical consequences of botulonium toxin a compared to medical treatment in patients with urge incontinence

Evaluation of the clinical consequences of botulonium toxin a compared to medical treatment in patients with urge incontinence

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230508058117N1
Enrollment
60
Registered
2023-11-20
Start date
2023-11-22
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urge incontinence. Urge incontinence

Interventions

Intervention 1: The first group: receive routine treatment of 200 units of botulinum toxin. Intervention 2: Group 2: They receive routine treatment with a single injection of 300 units of Botox into t

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Accurate diagnosis of patients with urge incontinence based on the diagnosis of a pelvic floor specialist, women over the age of 18, suffering from urge incontinence and in the case of a history of non-response to antimuscarinic drugs in the past 3 months; Urgent incontinence and having a history of antimuscarinic drug complications (constipation, blurred vision, dry mouth)

Exclusion criteria

Exclusion criteria: Patients with urinary tract infection, interstitial cystitis, having an intermittent or permanent catheter previous pelvic radiotherapy treatment neurogenic urge incontinence a history of sensitivity to Botox; Use of aminoglycoside drugs contraindications for receiving antimuscarinic treatment (tachyrhythmia, angle-closure glaucoma)

Design outcomes

Primary

MeasureTime frame
ICIQ-OAB questionnaire score. Timepoint: Before treatment, one week, 1 month after treatment. Method of measurement: Patient's answer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Hosseini Selaki Seri

Tehran University of Medical Sciences

hosseini.m.f.11@gmail.com+98 21 6119 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026